Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

Functional and computed tomographic evolution and survival of restrictive allograft syndrome after lung transplantation

“…From our current results, it seems that the FVC decrease appears to be more predictive towards survival than specific changes on the CT. This is comparable to interstitial pulmonary fibrosis (IPF), where most studies use FVC evolution as an endpoint and not CT evolution (11). However, some patients are often too sick to perform pulmonary function tests, which makes it more difficult to link evolutionary changes in CT and spirometry, especially in the later stages of the disease (12).…”

Idiopathic pulmonary fibrosis: The current state of the problem

“…Разработаны специальные режимы терапии при возникно-вении побочных эффектов. второй препарат, применяемый в Европе и США при ИфЛ, -пирфенидон [37][38][39][40]. в настоящее время ведется работа по его регистрации в Рф.…”

Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future

“…The IFIGENIA trial was a multicentre, double-blind, randomised, placebo-controlled phase III trial which evaluated the effect of a high dose of oral NAC (i.e. 600 mg three times daily) together with low dose of Pirfenidone Antifibrotic CAPACITY 1 [23] Pirfenidone Antifibrotic CAPACITY 2 [23] Pirfenidone Antifibrotic ACE-IPF [24] Warfarin Anticoagulant TOMORROW [25] BIBF 1120 Tyrosine-kinase inhibitor DANIELS [26] Imatinib mesylate Tyrosine-kinase inhibitor STEP-IPF [27] Sildenafil Phosphodiesterase-5 inhibitor BUILD-1 [28] Bosentan Endothelin-receptor antagonist BUILD-3 [29] Bosentan Endothelin-receptor antagonist ARTEMIS-IPF [30] Ambrisentan Endothelin-receptor antagonist MUSIC-IPF [31] Macitentan Endothelin-receptor antagonist RAGHU [32] IFN-c Immunomodulation INSPIRE [33] IFN-c prednisone and azathioprine compared with prednisone and azathioprine alone [20]. The primary endpoint was the change in vital capacity (VC) and diffusing capacity of the lung for carbon monoxide (DLCO) at 12 months.…”

“…Two similar trials, known as the CAPACITY trials (studies 004 and 006), have been carried out in North America, Australia and Europe for 72 weeks [23]. Patients with mild-to-moderate IPF were screened for eligibility using the following functional criteria: FVC o50% predicted; DLCO o35% predicted; and 6-min walk test (6MWT) distance o150 m. In study 004 the patients were assigned to receive either high-dose pirfenidone (2403 mg?day -1 ) or low-dose pirfenidone (1197 mg?day -1 ) or placebo; whereas in study 006 the patients were assigned to receive high-dose pirfenidone (2403 mg?day -1 ) or placebo.…”